Literature DB >> 639829

Correlation between serum concentration and pharmacological effect on atrioventricular conduction time of the antiarrhythmic drug propafenone.

K Keller, G Meyer-Estorf, O A Beck, H Hochrein.   

Abstract

Seven patients with cardiac dysrhythmias received a single, oral, therapeutically effective dose of the antiarrhythmic drug propafenone. The serum levels correlated well with changes in atrioventricular conduction times during the postabsorptive elimination phase (r = 0.8610, p less than 0.001). The mean half-lives of the serum level and the electrocardiographic effect (PQ-time) were 3.6 +/- .2 h and 3.8 +/- 0.6 h, respectively.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 639829     DOI: 10.1007/BF00606676

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

Review 1.  Antiarrhythmic drugs: electrophysiological and pharmacokinetic considerations.

Authors:  B I Sasyniuk; R I Ogilvie
Journal:  Annu Rev Pharmacol       Date:  1975       Impact factor: 13.820

2.  [Pharmacological and toxicological side effects of antifibrillatory substances].

Authors:  K Greeff
Journal:  Verh Dtsch Ges Kreislaufforsch       Date:  1969

Review 3.  Pharmacologic and clinical control of antiarrhythmic drugs.

Authors:  J T Bigger
Journal:  Am J Med       Date:  1975-04       Impact factor: 4.965

Review 4.  Antiarrhythmic agents. I. Mechanisms of action and clinical pharmacology.

Authors:  D T Mason; A N DeMaria; E A Amsterdam; R Zelis; R A Massumi
Journal:  Drugs       Date:  1973       Impact factor: 9.546

5.  [Propafenon, a new antiarrhythmic agent for the treatment of ectopic and rapid cardiac arrhythmias (author's transl)].

Authors:  O A Beck
Journal:  Med Klin       Date:  1975-01-17
  5 in total
  12 in total

1.  Antiarrhythmic efficacy of propafenone: evaluation of effective plasma levels following single and multiple doses.

Authors:  L Frabetti; B Marchesini; A Capucci; C Cavallini; S Gubelli; E Ambrosioni; B Magnani
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 2.  Is there an ideal antiarrhythmic drug? A review--with particular reference to class I antiarrhythmic agents.

Authors:  K A Muhiddin; P Turner
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

Review 3.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

Review 4.  Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

Review 5.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 6.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

8.  Effects of propafenone on calcium current in guinea-pig ventricular myocytes.

Authors:  C Delgado; J Tamargo; D Henzel; P Lorente
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

Review 9.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

10.  Propafenone for the treatment of severe ventricular arrhythmias.

Authors:  S W Rabkin; C E Rotem; K Boroomand-Rashti; B Bar-Shlomo
Journal:  Can Med Assoc J       Date:  1984-09-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.